Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIP4K2A | P48426 | 1/20 | 0.44 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117768 | 1.00 | PIP4K2A (0.44) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4120169 | 0.92 | CHRNA7 (0.49) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4120175 | 0.92 | CHRNA7 (0.49) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4103059 | 0.91 | HRH3 (0.52) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4102303 | 0.84 | HRH3 (0.51) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4109634 | 0.83 | CHRNB2 (0.57) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL4114272 | 0.83 | HRH3 (0.46) | PIP4K2APIP4K2BKCNH2HRH3 | |
| SCHEMBL4114755 | 0.81 | PIP4K2A (0.41) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4102255 | 0.80 | KCNH2 (0.60) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 | |
| SCHEMBL4108271 | 0.80 | KCNH2 (0.60) | PIP4K2APIP4K2BCHRNA7KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2604611-A1 | N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | claimed |
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | claimed |
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2604611-A1 | N-Biaryl substituted diazabicycloalkane derivatives as agonists of the alpha7 and alpha4beta2 nACh Receptor | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197860-A1 | BIARYL SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES | BRCA1, VHL, AADAC | PIP4K2A 796/4885PIP4K2B 1085/4885CHRNA7 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.